Assessment of Tumor Regression by Consecutive Pelvic Magnetic Resonance Imaging and Dose Modification during High- Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix.
- Author:
Taek Keun NAM
1
;
Byung Sik NAH
;
Ho Sun CHOI
;
Woong Ki CHUNG
;
Sung Ja AHN
;
Seok Mo KIM
;
Ju Young SONG
;
Mi Seon YOON
Author Information
1. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea. tknam@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Tumor regression;
Dose modification;
High- dose-rate;
Brachytherapy;
Cervical neoplasms;
Pelvic magnetic resonance imaging
- MeSH:
Brachytherapy*;
Cervix Uteri*;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Magnetic Resonance Imaging*;
Radiotherapy;
Rectum;
Regression Analysis;
Tumor Burden;
Urinary Bladder;
Uterine Cervical Neoplasms
- From:Cancer Research and Treatment
2005;37(3):157-164
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To assess tumor regression, as determined by pelvic magnetic resonance imaging (MRI), and evaluate the efficacies and toxicities of the interim brachytherapy (BT) modification method, according to tumor regression during multi-fractionated high-dose-rate (HDR) BT for uterine cervical cancer. MATERIALS AND METHODS: Consecutive MRI studies were performed pre-radiotherapy (RT), pre-BT and during interfraction of BT (inter-BT) in 69 patients with cervical cancer. External beam radiotherapy (EBRT) was performed, using a 10 MV X-ray, in daily fraction of 1.8 Gy with 4-fields, 5 d/wk. Radiation was delivered up to 50.4 Gy, with midline shielding at around 30.6 Gy. Of all 69 patients, 50 received modified interim BT after checking the inter-BT MRI. The BT was delivered in two sessions; the first was composed of several 5 Gy fractions to point A, twice weekly, using three channel applicators. According to the three measured orthogonal diameters of the regressed tumor, based on inter-BT MR images, the initial BT plan was modified, with the second session consisting of a few fractions of less than 5 Gy to point A, using a cervical cylinder applicator. RESULTS: The numbers of patients in FIGO stages Ib, IIa, IIb and IIIb+IVa were 19 (27.5%), 18 (26.1%), 27 (39.2%) and 5 (7.2%), respectively. Our treatment characteristics were comparable to those from the literatures with respect to the biologically effective dose (BED) to point A, rectum and bladder as reference points. In the regression analysis a significant correlation was observed between tumor regression and the cumulative dose to point A on the follow-up MRI. Nearly 80% regression of the initial tumor volume occurred after 30.6 Gy of EBRT, and this increased to 90% after an additional 25 Gy in 5 fractions of BT, which corresponds to 73.6 Gy of cumulative BED10 to point A. The median total fraction number, and those at the first and second sessions of BT were 8 (5~10), 5 (3~7) and 3 (1~5), respectively. The median follow-up time was 53 months (range, 9~66 months). The 4-year disease-free survival rate of all patients was 86.8%. Six (8.7%) patients developed pelvic failures, but major late complications developed in only two (2.9%). CONCLUSION: Our study shows that effective tumor control, equivalent survival and low rates of major complications can be achieved by modifying the fraction size during BT according to tumor regression, as determined by consecutive MR images. We recommend checking the follow-up MRI at a cumulative BED10 of around 65 Gy to point A, with the initial BT modified at a final booster BT session.
